In this context, it is noteworthy that relative to matched healthy control subjects (n = 463), increased systemic levels of PF4 have been reported in liver transplant recipients who developed lung cancer (n = 29; p = 0.02), actual PF4 concentrations were not shown, while platelet counts were numerically higher in the lung cancer group (210 × 109/L vs. 179 × 109/L; p = 0.08) [64]. The gene discussed is PF4; the disease is lung carcinoma.